Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — The White House is abandoning every single policy idea aimed at lowering prescription drug prices in President Biden’s domestic spending package, it announced Thursday morning.

Biden is effectively admitting he can’t overcome deeply entrenched pharmaceutical industry opposition to any change to the status quo, even with broad political support for the effort, and both chambers of Congress in Democratic control. The announcement came as part of an effort from Biden to put together a framework for a major domestic spending package that the entire Democratic caucus in Congress could support.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment